Genprex faces Nasdaq delisting over stock price, equity issues
Genprex , Inc., a pharmaceutical company based in Austin, Texas, has received notifications from The Nasdaq Stock Market indicating non-compliance with certain listing requirements. Currently trading ...
Zacks.com on MSN7d
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...
Le Lézard9d
Youdao to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 20
Youdao, Inc. ("Youdao" or the "Company") , an intelligent learning company with industry-leading technology in China, today announced that it will report its fourth quarter and fiscal year 2024 ...
Le Lézard9d
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy
Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows ...
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...
manilatimes9d
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Genprex doses first subject in expansion part of lung cancer gene therapy trial
Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene therapy ...
Business Wire23d
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
This important regulatory designation follows promising data from the ongoing global Phase 1a/1b study in patients with previously treated extensive-stage SCLC (ES-SCLC) after at least one prior ...
Pharmaceutical Technology23d
FDA grants ODD status to Zai Lab’s lung cancer treatment
The designation is granted based on promising data from the ongoing Phase Ia/Ib global trial of ZL-1310 in patients with extensive-stage SCLC (ES-SCLC) who have previously undergone a minimum of one ...
appliedclinicaltrialsonline23d
First Patient Dosed in Phase II Expansion Portion of Acclaim-3 Trial of Reqorsa in Combination With Tecentriq
The study program is evaluating Reqorsa (quaratusugene ozeplasmid) in combination with Genentech’s Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung ...